With Twitter (Now X) in Flux, Is #MedTwitter Under Threat?
Oncology professionals share what #MedTwitter means to them and where they might go if Twitter (now X) becomes obsolete.
All articles by Mark L. Fuerst
Less Than Half of NSCLC Patients Received Comprehensive Biomarker Testing in a Real-World Study
Most patients had at least 1 biomarker test, but only 46% had all 5 biomarker tests.
Perioperative Chemotherapy Matches Neoadjuvant Multimodal Therapy for Esophageal Cancer
Researchers found that CROSS is not inferior to MAGIC/FLOT, supporting it’s place in decision making for patients with locally advanced esophageal cancer.
Immunotherapy, Chemotherapy Combination Improves Survival in Advanced Esophageal Cancer
Researchers have identified a potentially new first-line treatment option for patients with advanced or metastatic esophageal squamous cell carcinoma.
Data Support Nivolumab Plus Chemo as Standard First-Line Therapy for Advanced Gastric, Esophageal Cancers
Nivolumab plus chemotherapy improved overall survival.
Update Supports Adjuvant Nivolumab as Standard Care in Resected Esophageal or Gastroesophageal Junction Cancer
Adjuvant nivolumab prolonged distant metastasis-free survival.
- Loading...
Loading...
Loading... 
Loading...